Bojan Radojicic

Bojan Radojicic

Auto-generated profile, based on publicly available information

Bojan Radojicic

Visoka zdravstveno-sanitarna škola strukovnih studija "Visan", Beograd

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Srpski arhiv za celokupno lekarstvo
Verified
Journal Article
Open access
PDF file
BRBojan Radojicic
Bojan Radojicic
MDMirko Dolic
Mirko Dolic
DTDjordje Tausan
Djordje Tausan
MRMarija Radojicic
Marija Radojicic
MMMiroslav Misovic
Miroslav Misovic
DKDejan Kostic
Dejan Kostic
Introduction/Objective. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection manifests with an unpredictable clinical course that could rapidly progress, leading to serious and often fatal complications. The identification of effective laboratory biomarkers that could stratify patients at risk of developing severe forms of the disease is imperative to ensure they receive prompt medical treatment. The aim of our study was to compare baricitinib and tocilizumab regarding clinical outcomes in hospitalized patients with severe COVID-19. Methods. A retrospective study included analysis of data from 82 patients of both sexes who were treated with biological immunosuppressive therapy at the Military COVID Hospital, Karaburma. All patients who met the criteria for use according to the guidelines of the national protocol for the treatment of COVID-19, version XIII, had a consultative decision made for the application of biological immunosuppressive therapy. Half were treated with tocilizumab, and the other half with baricitinib. Results. The results of our study show that the mortality rate is lower in the group treated with tocilizumab compared with the group treated with baricitinib: 17.1% vs. 26.8%, but without statistical significance (p = 0.286). Additionally, the use of tocilizumab reduces the need for mechanical ventilation compared with baricitinib: 53.6% vs. 68.3%, without statistical significance (p = 0.454). Conclusion. The results obtained in our study indicate that both drugs are equally clinically effective.

1 January 2022 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
BRBojan Radojicic
Bojan Radojicic
MRMarija Radojicic
Marija Radojicic
MMMiroslav Misovic
Miroslav Misovic
DKDejan Kostic
Dejan Kostic
Background/Aim. About 1.8 million new lung cancer cases are diagnosed worldwide every year, and about 1.6 million cases have a fatal outcome. Despite improvements in treatment in the previous decades, the survival of patients with lung cancer is still poor. The five-year survival rate is about 50% for patients with localized disease, 20% for patients with regionally advanced disease, 2% for patients with metastatic disease, and about 14% for all stages. The median survival of patients with untreated non-small cell lung carcinoma (NSCLC) in the advanced stage is four to five months, and the annual survival rate is only 10%. The aim of the study was to determine the results of treatment with concomitant chemoradiotherapy (CHRT) in terms of efficacy and toxicity in selected patients with advanced inoperable NSCLC. Methods. The study included data analysis of 31 patients of both sexes who were diagnosed and histopathologically verified with NSCLC in inoperable stage III and were referred by the Council for Malignant Lung Diseases to the Radiotherapy Department of the Military Medical Academy in Belgrade, Serbia for concomitant CHRT treatment. Upon expiry of the three months from the performed radiation treatment (RT), the tumor resonance was assessed based on multislice computed tomography (MSCT) examination of the chest and upper abdomen according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. According to the same criteria, progression-free survival (PFS), as well as overall survival (OS), was assessed every three months during the first two years, then every 6 months or until the onset of disease symptoms. Results. The median PFS was 13 months, and the median OS was 20 months. During and immediately after RT, 9 (29%) patients had a grade 2 or higher adverse events. Conclusion. The use of concomitant CHRT in patients in the third stage of locally advanced inoperable NSCLC provides a good opportunity for a favorable therapeutic outcome with an acceptable degree of acute and late toxicity and represents the standard therapeutic approach for selected patients in this stage of the disease.

19 November 2022 in arXiv
Verified
Preprint
Open access
PDF file
Zhongyuan ZhaoZhongyuan Zhao
Zhongyuan Zhao
BRBojan Radojicic
Bojan Radojicic
GVGunjan Verma
Gunjan Verma
ASAnanthram Swami
Ananthram Swami
SSSantiago Segarra
Santiago Segarra
We propose a throughput-optimal biased backpressure (BP) algorithm for routing, where the bias is learned through a graph neural network that seeks to minimize end-to-end delay. Classical BP routing provides a simple yet powerful distributed solution for resource allocation in wireless multi-hop networks but has poor delay performance. A low-cost approach to improve this delay performance is to favor shorter paths by incorporating pre-defined biases in the BP computation, such as a bias based on the shortest path (hop) distance to the destination. In this work, we improve upon the widely-used metric of hop distance (and its variants) for the shortest path bias by introducing a bias based on the link duty cycle, which we predict using a graph convolutional neural network. Numerical results show that our approach can improve the delay performance compared to classical BP and existing BP alternatives based on pre-defined bias while being adaptive to interference density. In terms of complexity, our distributed implementation only introduces a one-time overhead (linear in the number of devices in the network) compared to classical BP, and a constant overhead compared to the lowest-complexity existing bias-based BP algorithms.

1 January 2023 in Vojnosanitetski Pregled
Verified
Journal Article
Open access
PDF file
MMMiroslav Misovic
Miroslav Misovic
PAPredrag Aleksic
Predrag Aleksic
DKDejan Kostic
Dejan Kostic
MVMiodrag Vukovic
Miodrag Vukovic
BRBojan Radojicic
Bojan Radojicic
BCBojana Cikota-Aleksić
Bojana Cikota-Aleksić
Background/Aim. Prostate cancer (PCa) is second occurring carcinoma that affect males population. Although PCa incidence rates are high, most cases has favorable prognosis, with comfortable long term life quality. This study was aimed to assess distinction of lncRNA GAS5 plasma levels between healthy individuals and patients with PCa, and also between PCa patients with different prognostic scores. Methods. The present study included a total of 40 patients with PCa and a control group of 20 healthy individuals. PCa patients were divided into two subgroups (20 patients each) based on the prognostic criteria of American Joint Committee on Cancer. The patient data were collected and analysed. GAS5 levels were quantified using Real-time PCR metod. Statistical analysis was conducted using the IBM SPSS Statistics 26.0 computer program (IBM, USA, 2019). Results. The relative quantification of GAS5 expression levels shows downregulation in PCa patients compared to healthy individuals, however the difference was marginaly statistically significant (p = 0.056). With further analysis of the given results, we have concluded that the expression level of GAS5 was not significantly different in the first patient subgroup and the healthy individuals (p = 0.268). Patients from second subgroup had significantly lower plasma levels of GAS5 than healthy individuals (p = 0.033). Levels of GAS5 expression between patients with favorable prognosis (Group 1) than in the patients with worse prognostic score (Group 2), did not indicate the statistical significance (p = 0.275). In both Group 1 (p = 0.805) and Group 2 (p = 0.454), the plasma levels of GAS5 were not significantly different in comparing to the age (≤ 65 vs > 65 years). Conclusion. One of the main objective in PCa researching is identifying novel and more efficient biomarkers. Conducted research provides strong evidence about the significance of lncRNAs in PCa, as well as the correlation of decreased expression of GAS5 and poor prognosis in various tumours.

1 January 2024 in PONS - medicinski casopis
Verified
Journal Article
Open access
PDF file
BRBojan Radojičić
Bojan Radojičić
MDMirko Dolić
Mirko Dolić
MRMarija Radojičić
Marija Radojičić
Objective. Worldwide, breast cancer incidence is steadily rising. According to GLOBOCAN 2022, it ranks first in occurrence and second in mortality among women. The modern approach to breast cancer treatment is multidisciplinary. Surgery, drugs and radiotherapy, as well as their combinations, are applied in the order that depends on the stage of the disease, general condition, comorbidities. The results of previous studies have proven that in selected patients with early breast cancer there is no statistically significant difference in overall survival between partial resection followed by radiation therapy and mastectomy, which rapidly increased the number of breast conserving surgery. In this regard, it is a challenge to carry out postoperative radiotherapy of the breast with as few consequences as possible for the surrounding organs (heart and lungs), but also to minimize early and late reactions of the skin as well as the breast itself and, accordingly, radiation dermatitis (RD) is the most common complication that occurs in patients treated with radiotherapy. The aim of the study was to determine whether breast volume and age have an influence on the occurrence of more severe forms of acute skin toxicity. Methods. The research was conducted at the Radiotherapy Department of the Radiology Institute of the Military Medical Academy in Belgrade, and the study had a retrospective prospective character. The study included data analysis of 42 patients who were diagnosed with early breast cancer. After a breast conserving surgery was performed on them, with or without adjuvant chemotherapy, they were advised to undergo further treatment with postoperative radiation therapy. Results. All patients (100%) had a skin reaction. As treatment progressed and RD appeared or worsened, there was a tendency to increase in intensity of signs and symptoms. The percentage of mild forms of RD (gr I) was 52.4%, moderate (gr II) 35.7%, medium severe (gr III ) 11.9%, while there were no severe forms in the form of necrosis and ulceration. The average breast volume in RD grade I was 1542ml, grade II 1698ml, grade III 1988ml. The average age of subjects with acute RD is 66 years for grade I, 64 years for grade II, and 58 years for grade III. Conclusion. Using the 3D conformal technique, in local postoperative radiation therapy of the breast in the standard mode of fractionation in the supination position, breast volume and age have no statistical significance on the degree of acute skin toxicity

1 January 2026 in Medicinski glasnik Specijalne bolnice za bolesti štitaste žlezde i bolesti metabolizma
Verified
Journal Article
Open access
PDF file
MMMilorad Milivojević
Milorad Milivojević
Snežana KneževićSnežana Knežević
Snežana Knežević
BRBojan Radojičić
Bojan Radojičić
RZRada Zečević
Rada Zečević
IMIvan Marjanović
Ivan Marjanović
Excimer laser pulses using the LASIK method ablate the corneal stroma, achieving its remodeling to the desired optical characteristics. Besides correcting ametropia, it is desirable to minimize the induction of higher-order optical aberrations (HOA), as they affect the occurrence of glare and halos in night vision conditions. Fractional clearance (FC) represents the ratio of the treated optical zone (OZ) to the pupil diameter in scotopic lighting conditions. This study aims to examine the relationship between the enlargement of the treated OZ diameter and the increase in FC index on postoperative HOA levels. A prospective study included 37 subjects (74 eyes) with myopia treated with the LASIK method. The eye with a higher residual stromal bed value was treated with an OZ diameter of 7.0 mm, and the other eye of the same patient with an OZ diameter of 6.5 mm. After 6 months, an objective evaluation of optical outcomes was performed using an Analyzer device. The mean FC value in the group of eyes treated with OZ 6.5 mm is 2.138 (SD 0.30), and in the group treated with OZ 7.0 mm is 2.325 (SD 0.37), statistically significant (t=3.64; p<0.001). A smaller induction of all measured HOA was found when a wider OZ of 7.0 mm was treated, with the statistically significant reduction observed in spherical aberration induction. The increase in FC index is proportional to the enlargement of the treated OZ diameter. With an increase in FC value, the level of all HOA decreases after the LASIK procedure, with the most significant reduction observed in spherical aberration induction. Enlargement of OZ to 7.0 mm, when corneal structural characteristics allow it, improves postoperative optical outcomes.